Participated · Equity · Mar 2024

mPATH Health develops a digital cancer‑screening program that integrates automation and behavioral science to drive preventive care. The company says its program has demonstrated the ability to double screening rates across diverse populations regardless of race, ethnicity, income, or literacy level. mPATH plans to expand its screening and preventive health modules and to conduct additional rigorous clinical testing supported by grant funding. The platform emphasizes personalized outreach to identify, educate, and ensure timely access to relevant screenings, with a stated commitment to health equity. The recent funding is intended to accelerate growth, expand reach, and document return on investment for health systems and insurers. mPATH Health integrates automation and behavioral science to improve preventive cancer screening. Led by CEO and Founder Dr. Dave Miller, the company uses plain language, engaging animations, and video testimonials to inform, motivate, and empower individuals to request and complete evidence-based screenings. mPATH is currently in use across three healthcare systems in North Carolina for colorectal and lung cancer screening, and a fourth major healthcare system will launch the program in March. The company raised $1.1M consisting of $706K in angel investments and $400K from a National Cancer Institute Small Business Technology Transfer grant. mPATH plans to use the funds to develop new modules for other preventive care needs, add artificial intelligence to guide its outreach, and accelerate its growth trajectory.

Participated · Seed · Mar 2023

Loupe offers art streaming services that display contemporary artworks—including fine art, photography, street art, digital, NFT and motion art—across customizable channels and algorithmic playlists. The platform uses patented software to ingest digital assets and user preferences to create ambient entertainment experiences, and currently represents more than 700 artists and 50+ channels. Loupe maintains over a dozen streaming relationships with platforms such as Amazon Fire, Apple TV, Comcast Xfinity, Google TV, LG Channels, Samsung TV Plus, Sling TV, Xumo, ViX, FreeCast and Vizio WatchFree+. The company recently launched Loupe for Business, a solution for out-of-home markets (hospitality, healthcare) to schedule and tailor branded art experiences by location and time. Led by Founder and CEO Dot Bustelo, Loupe plans to use new funding to drive lead generation around branded content, build consumer awareness, and expand streaming partnerships with major media and hospitality companies in 2023. The company raised $3M in a Seed+ round to support these strategic priorities.

Participated · Series A · Dec 2020

Aperiomics, founded in 2014 and based in Sterling, Virginia, develops a next‑generation genomic testing platform designed to identify every known pathogen from a single sample. The company quickly launched a COVID-19 test in March. Management says the platform will be made available to more doctors and integrated into the healthcare system as a new gold standard in diagnostic testing. Financially, Aperiomics closed its Series A at $3 million after adding $1.2 million to an initial $1.8 million announced in August 2019. The company has also launched a $1 million bridge note to fund operations until a Series B; the bridge is led by Tamiami Angel Fund IV, which has committed $300,000 and will include executive investments. Series A investors include VentureSouth, Pipeline Angels, Atlanta Technology Angels, The Launch Place and the Central Texas Angel Network. Aperiomics applies Deep Shotgun Metagenomic Sequencing and the Xplore-PATHOSM test to identify every bacterium, virus, fungus and parasite known to modern science. The Xplore-PATHOSM Test combines advanced DNA testing, big data and infectious disease expertise to identify the root cause of infectious diseases. By offering unbiased microbial insight, the company aims to help healthcare providers prescribe more precise treatments. Led by CEO Dr. Crystal Icenhour, Aperiomics recently expanded into a new 4,700 square foot facility in Sterling, Virginia and is constructing an on-site laboratory to be completed and certified in the coming months. The company plans to use new funding to increase the number of patients served and clinicians partnered with, and to make major investments in research and development.

Participated · Series A · Jan 2020

OncoLens develops oncology-focused AI that extracts key insights from structured and unstructured clinical, molecular, and lab data to identify patients who may have missed treatment-defining diagnostics or therapies in real time. Its collaboration solutions help cancer centers coordinate next steps to ensure timely, multidisciplinary action. The company serves national cancer institutes, academic medical centers, and community-based integrated delivery networks, and also operates internationally after launching in the EMEA region in 2022. With a growing customer base, OncoLens launched the OncoLens Research Network to partner with life‑science commercial, real‑world evidence, and clinical development teams to bring trials and quality-improvement initiatives to its centers. For life‑science partners the company offers access to a diverse, community-focused network to address RWE, diversity and inclusion in trials, and to find patients with rare genomic alterations. The company is led by CEO Anju Mathew and recently raised capital to expand its development efforts. OncoLens provides an integration and collaboration platform to cancer centers that enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure it drives intra-enterprise, community, and network participation in multidisciplinary care planning, tracking, and delivery. Patients can collaborate on treatment plans, track quality for accreditation, and align to care pathways, while health systems can maximize clinical trial participation and referral streams. The company supports creation of centers of excellence that can be leveraged for patient care and provider education. It serves more than 200 cancer centers in the U.S. and has clients in the larger EMEA region. Led by CEO Anju Mathew, OncoLens intends to use the new funds to expand domestic and global footprint into rural communities and low- and middle-income countries to improve capacity, access, and diversity in research. The financial terms of the investment were not disclosed. OncoLens offers a collaborative, HIPAA-compliant tumor board and cancer treatment planning platform that aggregates patient-specific data across EMR, clinical, and genetics systems and provides decision support. Its software includes virtual tumor board technology, workflow automation, survivorship care planning, and clinical decision support to standardize care and improve efficiencies. The platform automatically identifies patient-specific clinical trials at a facility or affiliates and surfaces relevant NCCN/ASCO guidelines and the latest research to support care teams. OncoLens is used or being implemented across several National Cancer Institute-designated cancer centers and large U.S. healthcare delivery networks, and currently serves more than 8,000 cancer care providers. The company has received market recognition with studies showcased in professional journals and conferences. Management says the new funding will accelerate product development and market expansion as it builds on its position in tumor board and treatment-planning software. OncoLens develops tumor board and cancer treatment planning software that consolidates clinical, radiological, and pathological data to streamline multidisciplinary case discussions. Its platform includes an intelligent workflow engine that automates accreditation and quality reporting, facilitates survivorship care planning, and supports more informed clinical decision-making. The company uses proprietary algorithms to reduce clinician workload by matching patients with relevant clinical trials and potential targeted therapies. OncoLens currently serves several large integrated delivery networks (IDNs) and hospitals across the U.S. Led by co-founder and CEO Anju Mathew, the company plans to expand its product capabilities and grow sales and marketing resources using new funding. The recent financing strengthens its position to scale adoption among health systems. OncoLens offers a Software-as-a-Service platform that enables diverse, multispecialty cancer care teams to collaborate on individual patient treatment plans. The platform provides cancer-specific clinical decision support, helps programs track and implement nationally approved quality metrics, and surfaces applicable clinical trials. It consolidates case data and workflows to streamline tumor board management and survivorship care planning, reducing the manual data-aggregation burden described in the article. OncoLens says its solution decreases a cancer center’s workload and saves resources by standardizing discussions and integrating multiple workflows. The company recently closed a $1.35 million seed round to fund strategic growth and product expansion. OncoLens is part of Georgia Tech’s ATDC Accelerate portfolio and has received industry recognitions, including an “Exceptional Research Award” from the Academy of Oncology Nurse Navigators.

Led · Series A · Nov 2019

MooveGuru is an Atlanta-based proptech that provides a mover engagement platform and operates the YourHomeHub and HomeKeepr brands. Led by CEO and founder Scott Oakley, the company wholly owns HomeKeepr and recently launched YourHomeHub, an "everything home" platform that lets homeowners manage financial and physical aspects of their homes. The company reports connections to more than 2,000 brokerages, 316,000 agents (the article also notes 320,000 agents use MooveGuru and HomeKeepr), and millions of homeowners; over 110,000 Keller Williams agents are on the network. MooveGuru holds exclusives with ERA Real Estate, Better Homes and Gardens Real Estate, Exit Realty, Realty Executives, Vylla, and HomeScout, and has preferred vendor relationships with REMAX and Berkshire Hathaway. The company says it will use the newly raised funds to continue to expand operations and its business reach. MooveGuru is a Roswell, GA‑based provider of a mover engagement program for real estate agents and brokers. Led by CEO Scott Oakley, the company offers a moving concierge solution to brokerage firms, with services from change of utilities to full hands‑free moves. Today more than 300 brokerages, their agents, and clients are connected to the MooveGuru platform. ERA Sunrise will provide the service to more than 1,200 clients in the Atlanta, Athens, and Augusta regions of Georgia. The company closed a $1.9M Series A round (including converted debt) and intends to use the funds to expand its regional workforce to support sales growth.